Grobbee EJ, de Jong VD, Schrieks IC, Tushuizen ME, et al. Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-alpha/gamma agonist aleglitazar. PLoS One 2022;17:e0277706.
PMID: 36378671